Cargando…
Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies
The globalization of clinical trials has accelerated recent advances in multiple myeloma (MM). However, it is unclear whether trial enrollment locations are reflective of the global burden of MM and whether access to novel therapies is timely and equitable for countries that participate in those tri...
Autores principales: | Fatoki, Raleigh Ayoolu, Koehn, Kelly, Kelkar, Amar, Al Hadidi, Samer, Mehra, Nikita, Mian, Hira, Landgren, Ola, Kazandjian, Dickran, Hoffman, James, Sborov, Douglas W., Mohyuddin, Ghulam Rehman |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470137/ https://www.ncbi.nlm.nih.gov/pubmed/35960904 http://dx.doi.org/10.1200/GO.22.00119 |
Ejemplares similares
-
Is aggressive treatment of smoldering myeloma the path to curing myeloma?
por: Chakraborty, Rajshekhar, et al.
Publicado: (2023) -
The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma
por: Tariq, Syed Maaz, et al.
Publicado: (2023) -
Hospitalization at the end of life in patients with multiple myeloma
por: Abbasi, Saqib, et al.
Publicado: (2021) -
Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials: A Systematic Review
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2021) -
Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma
por: Najjar, Mimi, et al.
Publicado: (2023)